Oppenheimer Initiates Coverage on Y-mAbs Therapeutics (NASDAQ:YMAB)

Oppenheimer began coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research note issued to investors on Monday morning, MarketBeat.com reports. The firm issued an outperform rating and a $23.00 target price on the stock.

Several other research analysts have also recently commented on the stock. HC Wainwright restated a “buy” rating and set a $22.00 target price on shares of Y-mAbs Therapeutics in a report on Friday, November 15th. Canaccord Genuity Group restated a “buy” rating and issued a $26.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. Finally, Wedbush restated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $21.38.

Y-mAbs Therapeutics Price Performance

NASDAQ YMAB opened at $10.10 on Monday. Y-mAbs Therapeutics has a one year low of $5.29 and a one year high of $20.90. The firm has a market cap of $452.38 million, a P/E ratio of -18.70 and a beta of 0.68. The stock’s 50-day moving average is $13.82 and its 200-day moving average is $12.95.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The company had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. During the same period in the previous year, the firm posted ($0.18) EPS. Equities analysts anticipate that Y-mAbs Therapeutics will post -0.64 EPS for the current year.

Insider Activity at Y-mAbs Therapeutics

In related news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the sale, the chief operating officer now directly owns 30,600 shares in the company, valued at $449,514. The trade was a 14.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Thomas Gad sold 65,000 shares of the stock in a transaction on Friday, September 13th. The stock was sold at an average price of $13.47, for a total value of $875,550.00. Following the transaction, the insider now owns 97,681 shares in the company, valued at $1,315,763.07. The trade was a 39.96 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 100,000 shares of company stock worth $1,338,100. Company insiders own 22.50% of the company’s stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

A number of institutional investors have recently modified their holdings of YMAB. Ameritas Investment Partners Inc. boosted its holdings in Y-mAbs Therapeutics by 39.9% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after purchasing an additional 1,056 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Y-mAbs Therapeutics by 8.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock valued at $345,000 after buying an additional 1,657 shares in the last quarter. Caxton Associates LP acquired a new stake in shares of Y-mAbs Therapeutics in the first quarter valued at approximately $306,000. Boston Partners bought a new stake in shares of Y-mAbs Therapeutics in the first quarter valued at approximately $556,000. Finally, Bank of New York Mellon Corp grew its position in Y-mAbs Therapeutics by 8.0% during the second quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock worth $1,461,000 after buying an additional 8,974 shares in the last quarter. Institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.